ReviewDiscover oncology2025
Research progress on ADAM28 in malignant tumors.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics analyses reveal steroid hormone and antioxidant pathways regulating sperm storage capacity in female Muscovy ducks (Cairina moschata).Poultry science · 2026Article
- The ADAM Family of Proteases: Structure, Substrates, and Roles in Liver Diseases.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A disintegrin and metalloproteinase (ADAM) 28 belongs to the zinc-dependent metalloproteinase superfamily and has a signal sequence at its N-terminus that can direct the protein into the secretory pathway. ADAM28 is a multifunctional protein that has been shown to play a role in regulating numerous biological processes, including cell adhesion, cell fusion, membrane protein shedding, protein hydrolysis, and signaling pathway modulation. ADAM28 is highly expressed in numerous malignant tumors and plays a pivotal role in the proliferation, metastasis and drug resistance of these tumors by acting on substrates such as IGFBP-3, vWF and CTGF, thereby promoting PSGL-1/P-selectin-mediated cell adhesion. Consequently, inhibiting ADAM28 could impede tumor proliferation, metastasis and drug resistance, which suggests that ADAM28 may serve as a prognostic indicator of and potential therapeutic target for malignant tumors. In this article, the structure and function of ADAM28 and its correlation with the onset and progression of human malignant tumors are primarily examined. Additionally, the potential applications of ADAM28 in tumor research are investigated to offer a theoretical foundation and reference for the clinical diagnosis and treatment of malignant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.